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Abstract
Background: Postembryonic development, including metamorphosis, of many animals is under control of hormones. In
Drosophila and other insects these developmental transitions are regulated by the coordinate action of two principal
hormones, the steroid ecdysone and the sesquiterpenoid juvenile hormone (JH). While the mode of ecdysone action is
relatively well understood, the molecular mode of JH action remains elusive.
Methodology/Principal Findings: To gain more insights into the molecular mechanism of JH action, we have tested the
biological activity of 86 structurally diverse JH agonists in Drosophila melanogaster. The results were evaluated using 3D
QSAR analyses involving CoMFA and CoMSIA procedures. Using this approach we have generated both computer-aided
and species-specific pharmacophore fingerprints of JH and its agonists, which revealed that the most active compounds
must possess an electronegative atom (oxygen or nitrogen) at both ends of the molecule. When either of these
electronegative atoms are replaced by carbon or the distance between them is shorter than 11.5 A ˚ or longer than 13.5 A ˚,
their biological activity is dramatically decreased. The presence of an electron-deficient moiety in the middle of the JH
agonist is also essential for high activity.
Conclusions/Significance: The information from 3D QSAR provides guidelines and mechanistic scope for identification of
steric and electrostatic properties as well as donor and acceptor hydrogen-bonding that are important features of the
ligand-binding cavity of a JH target protein. In order to refine the pharmacophore analysis and evaluate the outcomes of the
CoMFA and CoMSIA study we used pseudoreceptor modeling software PrGen to generate a putative binding site surrogate
that is composed of eight amino acid residues corresponding to the defined molecular interactions.
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Introduction
Many aspects of the postembryonic development and repro-
duction of Drosophila and other insects are regulated by the
coordinate action of two principal hormones, the steroid 20-
hydroxyecdysone (hereafter referred to as ecdysone) and sesqui-
terpenoid juvenile hormone (JH). Mode of ecdysone action is
relatively well known, in part due to extensive research in
vertebrate steroid endocrinology that supported research on
ecdysone action in Drosophila and other insects [1,2]. On the other
hand, the molecular mechanism(s) underlying JH action remain
enigmatic; our incomplete understanding of JH action is not due
to a lack of effort [3–6], but rather originates from the uniqueness
of JH as a hormone [7].
The chemical nature of JH was suggested after JH activity was
identified as farnesol derivatives in Tenebrio molitor excrements [8].
In the late 1960s, the first of several JH homologues were
chemically identified [9]. Most insects have so called JH-III (epoxy
farnesoic acid methyl ester) as natural juvenile hormone [10]. The
hormone plays critical roles in a rich array of processes, including
development, reproduction, behavior, pheromone production,
adult diapause, polyphenism, and morph and caste determination
[11,12]. Perhaps most intriguing are the functions of JH associated
with metamorphosis and reproduction [13–15].
Though Gilbert et al. [16] in one of his reviews wrote, in all of
endocrinology there is no more wondrous name for a hormone
than the insect juvenile hormone,‘‘ its molecular and cellular
modes of action are yet to be understood. Many laboratories and
agrochemical companies have synthesized over 4000 analogs
(agonists) of JH and these have been tested on hundreds of insect
species as potential insecticides [17–22]. In terms of chemical
synthesis, no other hormone in the animal kingdom or human
medicine led to the production of so many agonists. Still, none of
JH analogs have been used as widely as less specific and sometime
toxic insecticides (e.g. chlorinated hydrocarbons, organophos-
phates, phenothiazines, pyrethroids, neonicotinoids, dinitrophenol
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Drosophila, though perhaps the best known representative of
cyclorrhaphous diptera and an ideal genetic model organism,
was mostly ignored in this research effort, as it is not a pest. Only a
limited number of JH analogs (also known as juvenoids) were
tested in Drosophila [23–27] and their structure-activity relation-
ships were never evaluated.
In the genomic era, studies utilizing Drosophila offer considerable
hope to understand the molecular mechanism of JH action and to
identify the JH receptor, and thus to explain the plethora of data
accumulated in the past four decades on JH. Here, we report
results that characterize the precise pharmacological relationships
of JH and its putative target in Drosophila. Such molecular analyses
has proven to be a very useful tool in elucidating the molecular
action of many compounds, including drugs, and predicting new
pharmaceutically successful compounds. Examples include steroid
agonists and antagonists [28], acetylcholinesterase inhibitors for
Alzheimer symptoms treatment [29], dopamine receptor agonists
[30], antimalarial drugs [31] and multidrug resistance modulators
[32]. To gain insight into the molecular mechanism of JH action
we first tested the biological activity of 86 JH agonists in a
Drosophila morphogenetic assay. We then related these data to 3D
QSAR–CoMFA and CoMSIA analyses (comparative molecular
field analysis, comparative molecular similarity indices analysis,
respectively). The widely used CoMFA calculates steric and
electrostatic properties according to Lennard-Jones and Coulomb
potentials. The more recently reported CoMSIA approach
calculates similarity indices in the space surrounding each of the
aligned molecules within the experimental set, and in addition to
steric and electrostatic properties it calculates also hydrogen bond
donor, hydrogen bond acceptor and hydrophobic fields [33].
CoMSIA is believed to be less affected by changes in molecular
alignment and provides smooth and interpretable contour maps
due to employing a Gaussian-type function. Using this approach
we produced the first computer-aided and species-specific
pharmacophore analysis of JH and its agonists. These revealed
that the most active compounds for Drosophila need to have an
electronegative atom (oxygen or nitrogen) at both ends of the
molecule. When these electronegative atoms are replaced by
carbon, or the distance between them is shorter than 11.5 A ˚ or
longer than 13.5 A ˚, their biological activity is decreased
dramatically. They also showed that an electron deficient moiety
in the middle of the JH agonist molecule is essential for high
biological activity. The information obtained from CoMFA and
CoMSIA contour maps identified the steric and electrostatic
properties that are important features of ligand-binding cavity of
JH target protein, a putative JH receptor. To refine this
pharmacophore and evaluate alignment and the outcomes of the
CoMFA and CoMSIA studies, we used the pseudoreceptor
modeling software PrGen to generate a putative atomistic binding
site model.
Results
Biological activity and structural diversity of JH agonists
We tested the biological activity of set of 86 JH analogs whose
members spanned the range of structural diversity seen in JH
agonists (Figure 1 and Figure 2A, see also Supporting Table S1).
Although JH agonists belong to various chemical entities (farnesol
and geraniol derivatives, trimethyl or tetramethyl-dodecenoate or
undecenoate derivatives, juvabions, various derivatives of benzoic
acid, acetophenone, aniline, nitrophenol, halophenol, benzenesul-
phonic acid or carbamate, then v-alkoxy-v,v-dimethyl deriva-
tives, oxime ethers, phenoxyphenoxy and other oligocyclic
derivatives and peptidic juvenoids), from a structural point of
view, the compounds we tested can be divided into two large
classes. The first are linear flexible terpenoid or terpenoid-related
molecules with several freely rotable bonds that include also
natural JH-I, JH-II and JH-III (Class I structures 1–3). The second
are class with more rigid compounds containing phenoxy or other
cyclic groups on both ends of the molecule exemplified by ZR-
10183, ZR-10131 and pyriproxyfen (Class II structures 81, 85,
86). Though many CoMFA reports have shown that it is difficult
to use the analysis of flexible molecules to generate a CoMFA
model, and many of the molecules used in this study have linear,
flexible structure, the model presented here that is based on the
superposition of both structurally diverse compound classes has
acceptable predictive ability. Figure 1 shows the biological activity
of selected 16 agonists whereas Supporting Table S1 shows the
biological activity of all tested 86 agonists. This activity is
expressed as ED50, and ranges from 0.00005 to 10 mg (0.0002 to
40.8163 nM) per animal where picogram amounts reflect most
active compounds. JH agonists that show biological activity above
1 mg/animal can be considered as non-active.
Optimizing the CoMFA model
We found that highly active compounds in both Class I and
Class II have an electronegative oxygen at both of their ends or a
nitrogen replacing the oxygen at one end (1–3, 14–17, 19, 81–
86). The biological activity dramatically decreases when these
oxygens or the nitrogen are replaced by carbon (e.g. 25, 26, 29,
31, 32, 43, 44). We were therefore interested in understanding
how these atoms contributed to different longitudinal shifts of the
structures in the alignments.
The nitrogen present in JH agonists is mostly part of an
unsaturated heterocycle, carbamate or amide whereas the oxygen
is mostly found within esteratic, etheric, epoxide or phenoxyphe-
nol groups (see Figure 1 and Supporting Table S1). The oxygen in
the phenoxyphenol group within Class II compounds is strongly
sterically hindered by benzene rings and its free electron pairs
participate in the conjugation system with phenyl rings. This
makes the phenoxyphenol oxygen poorly reactive for intermolec-
ular interactions including hydrogen bonding. On the other hand,
the oxygen in the epoxy moiety in Class I compounds will provide
electron pairs for H-bonding or for other electrostatic interaction
very easily. On the opposite side of all compounds the oxygen is
part of an esteratic group whereas the nitrogen is part of a
carbamate, amide group or heterocycle where all these provide
relatively weak interaction potential. Thus, the oxygen and
nitrogen in the different compounds have very different chemical
reactivities, atom charges and abilities to form hydrogen bonds or
electrostatic interactions. These different properties pose challeng-
es for generating an acceptable alignment of JH agonists. Since
structural alignment is crucial step in CoMFA, we considered
these aspects of the properties of JH agonists as we constructed
multiple CoMFA models to identify an appropriate alignment.
Initially,wegeneratedseveralvariantsofanalignmentcontaining
the entire set of compounds (Supporting Figure S1). We optimized a
CoMFA model by creating a training set from 76 compounds and a
test set containing ten structures representing both classes of
compounds (linear and cyclic). All of the alignments were produced
with respect to the electronegative oxygens or nitrogens located at
the ends of the molecules. The alignment with the best statistical
parameters was used for the final CoMFA model.
Many flexible linear compounds (e.g. 14, 15, 17, 19, 22, 23, 26)
are 1.56longer in their extended conformation than typical rigid
cyclic compounds (56, 66, 72, 74, 80–86). Thus, shorter bent
conformations with low energy were selected as they fit better
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PLoS ONE | www.plosone.org 2 June 2009 | Volume 4 | Issue 6 | e6001Figure 1. List of 16 representative JH agonists and their biological activities in Drosophila morphogenetic assay. The biological activity
(ED50) is expressed in mg of the compound per animal, then it is converted to nmol per animal, and finally to -log of nmol values that are used for
CoMFA and CoMSIA computations. Compounds 1–28 represent Class I agonists, whereas compounds 35–86 within this Table represent Class II
agonists. Complete list of tested JH agonists is provided under Supporting Table S1. 1=(2E,6E)-9-((2R)3,3-Dimethyl-oxiranyl)-3,7-dimethyl-nona-2,6-
dienoic acid methyl ester (JH-III, also known as methylepoxyfarnesoate). 6=(2E,6E)-(S)-10,11-Dihydroxy-3,7,11-trimethyl-dodeca-2,6-dienoic acid (JH-
III acid diol). 12=(E)-(R)-11-Chloro-3,7,11-trimethyl-dodec-2-enoic acid methyl ester. 16=Tioethyl-(2E,4E)-(R)-11-methoxy-3,7,11-trimethyl-2,4-
dodecadienoate (triprene; ZR-619). 23=(2E,4E)-(R)-11-Methoxy-3,7,11-trimethyl-dodeca-2,4-dienoic acid diethylamide (ZR-618). 27=(2E,4E)-(R)-
3,7,11-Trimethyl-dodeca-2,4-dienoic acid prop-2-ynyl ester (kinoprene; ZR-777). 28=2-((E)-(8R,9S)-9-Ethoxy-4,8-dimethyl-dec-3-enyl)-2-methyl-(2R,3S)-
cyclopropanecarboxylic acid isopropyl ester (ZR-4429). 35=(R)-3-[5-(3-Ethyl-phenoxy)-3-methyl-pentyl]-2,2-dimethyl-oxirane. 39=(R)-3-[5-(3-
Pharmacology of JH Agonists
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2. Varying the
energy cut off from 10 to 30 kcal/mol did not have a significant
effect on the predictive ability of the model. The best q
2 was
achieved with a column filtering of 1 kcal/mol. A non-cross-
validated PLS analysis was performed, and the final parameters
and statistics (q
2=0.508, r
2=0.948) for the common training set
(designated Class I+II) are summarized in the first row of Table 1.
The predictive ability was externally evaluated through the
prediction of a test set consisting of 10 ligands representing both
Class I+II compounds with CoMFA predictive coefficient r
2=0.49
and CoMSIA predictive coefficient r
2=0.51 (Supporting Table
S3) or of 5 Class I ligands with CoMFA r
2=0.54 and CoMSIA
r
2=0.59 (Supporting Table S4), and 5 Class II ligands with
CoMFA r
2=0.60 and CoMSIA r
2=0.63 (Supporting Table S5).
In a second approach, we considered the above mentioned
diversity of JH agonist structures and split their common
Figure 2. The superpositional alignment of congeners of JH agonists analyzed in this study. Complete set of all 86 JH compounds is
shown in A, whereas B shows alignment of two selected agonists, natural JH-III (1) as representative of Class I and the most rigid structure of ZR-
10852 (82) as representative of Class II.
doi:10.1371/journal.pone.0006001.g002
Ethoxymethoxy-phenoxy)-3-methyl-pentyl]-2,2-dimethyl-oxirane. 41=(R)-3-{[(E)-4]-4-Chloro-phenoxy)}-3-methyl-but-3-enyl]-2,2-dimethyl oxirane.
48=5-[(E)-4-((2R,3S)-3-Ethyl-3-methyl-oxiranyl)-2-methyl-but-1-enyloxy]-benzo-[1,3]-dioxole. 53=(S)-4-{2-[3-(2,2,2-Trichloro-acetyl)-ureido]-propiony-
lamino}-benzoic acid ethyl ester. 57=[2-(4-Phenoxy-phenoxy)-ethyl]-carbamic acid ethyl ester (fenoxycarb). 62=(R)-2-[1-Methyl-2-(4-phenoxy-
phenoxy)-ethoxy]-thiazole. 80=(S)-{2-[4-(1,4-Dioxa-spiro-[4,6]-undec-6-ylmethyl)-phenoxy]-ethyl}-carbamic acid ethyl ester. 86=2-[1-Methyl-2-(4-
phenoxy-phenoxy)-ethoxy]-pyridine (pyriproxyfen; Sumitomo 31183)
doi:10.1371/journal.pone.0006001.g001
Pharmacology of JH Agonists
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structurally diverse Class I and Class II compounds. This split led
to separate CoMFA calculations and allowed us to explore how JH
agonist structural diversity affected the CoMFA result. The two
independent training sets showed nearly ideal alignment and
markedly better statistical parameters than the initial, common
training set. When CoMFA calculations of separated Class I and
Class II subsets were performed, the final statistical parameters for
each individual set (Class I: q
2=0.576, r
2=0.983; Class II:
q
2=0.686, r
2=0.987) are significantly better than for entire set
(I+II) (see rows two and three of Table 1). The calculated versus
actual 2log ID values of compounds in the test sets of Class I and
Class II are shown in Supporting Figures S2 and S3, and the
calculated versus actual 2log ID values for all tested agonists are
shown in Supporting Table S2.
Optimization of the CoMSIA model
Standard steric and electrostatic fields, donor and acceptor
hydrogen-bonding fields and hydrophobic fields were tested in the
CoMSIA model and optimized as a function of energy cut off and
column filtering. The statistical evaluation for the CoMSIA
analyses was performed on the different versions of the dataset
chosen during optimizing of the CoMFA model.
When we analyzed the whole set of structures, both Class I and
II, the indicator fields yielded the most promising statistical results.
Table 2 summarizes the optimized parameters and q
2 values for
the indicator fields. A model with a q
2 value greater than 0.3 is
usually considered to be significant, so models with field indicators
that led to q
2,0.3 were not considered. The best PLS analysis
gave the following values at n=76: q
2=0.534, r
2=0.901.
Electrostatic factors played a major role as in the best CoMSIA
model, the contribution of electrostatic field gave a high value of
0.740 versus 0.260 for steric factors (Table 2). Another significant
descriptor was an acceptor hydrogen bond field although its q
2 was
only 0.391. The graphical contour maps of the sterical and
electrostatic fields are similar to the corresponding CoMFA plots.
The significant q
2 value of a combination of steric, electrostatic
and hydrogen bonding descriptors illustrate that these variables
are necessary to describe interaction of JH compound with its
target.
When the set of agonists was divided into Class I and Class II
structures and separate CoMSIA calculations performed, the
differences between these two classes became more remarkable.
This can be seen in the different types of indices producing the best
models of separated agonist classes. The final statistical parameters
of both classes (Class I: n=45, q
2=0.637, r
2=0.960 for steric and
electrostatic indices; Class II: n=31, q
2=0.755, r
2=0.956 for
steric index) are summarized in Table 2 and graphically
interpreted in Supporting Figures S4 and S5.
3D QSAR outcomes
In order to visualize the information content of derived CoMFA
model, 3D electrostatic and steric contour maps were generated
(Figures 2A and 2B). The importance of the electronegative
oxygens or nitrogens at the ends of the aligned structures is
indicated by red polyhedra near the positions of these atoms. The
presence of smaller red polyhedra in the middle of a JH agonist
structure indicates an additional site where an electronegative
atom or group enhances the biological activity, as exemplified by
the oxygen in the middle of SJ-68 oxid (9) or double bond in JH-
III (1). The contour map of Class II (Figure 3B) differs from that of
Class I (Figure 3A) mainly in the steric fields. The large green
polyhedra seen in the Class II map lie near the phenoxyphenyl
group and indicate that the presence of steric bulk substituents in
this part of the molecule enhance biological activity.
CoMSIA contour maps are easier to interpret than CoMFA
maps as they partition variance into the different field types. The
contour maps for the steric and electrostatic CoMSIA fields are
shown in Figures 3A (Class I) and 3B (Class II). The green
polyhedra, as in the CoMFA contour maps, represent sterically
favored regions in which more bulky substituent increase
biological activity, while yellow polyhedra represent sterically
disfavored regions where a less bulky substituent can increase
activity. In the CoMSIA electrostatic contour plot, red polyhedra
represent favorable regions where negatively charged groups
enhance activity while blue polyhedra represent disfavored regions
where positively charged groups enhance activity. The steric and
electrostatic fields of CoMSIA maps are generally in good
accordance with the field distribution of CoMFA maps. They
do, however, indicate more sterical freedom for Class II
compounds on their phenoxyphenol side.
A more dramatic difference between Class I and Class II
compounds appears in the CoMSIA hydrogen bond acceptor and
donor fields (Figures 3C and 3D). These highlight the areas
beyond ligands where putative hydrogen bond partners (amino
acid residues) in the putative receptor could form hydrogen bonds.
Magenta areas indicate where hydrogen bond acceptors are
favorable for increasing biological activity (oxygens and nitrogens
Table 1. Summary of results from CoMFA analyses for the common, unseparated training set of 76 JH agonists as well as for this
set split into Class I and Class II compounds.
Cross-validated Non- cross-validated Fraction
Class n Comp q
2 SPRESS r
2 SEE F test S E
I+II 76 6 0.508 0.969 0.948 0.306 196,93 0.426 0.574
I 45 6 0.576 1.007 0.983 0.202 325.47 0.403 0.597
II 31 6 0.686 0.767 0.987 0.155 308.77 0.524 0.466
Legend:
n=number of compounds.
Comp=number of PLS components in analysis.
q
2=Squared correlation coefficient of a cross-validated analysis.
SPRESS=Standard deviation of error of prediction.
r
2=Standard correlation coefficient of a non-cross-validated analysis.
SEE=Standard deviation of a non-cross-validated analysis (Standard error of estimate).
Fraction=Field contribution from CoMFA, S=steric, E=electrostatic.
doi:10.1371/journal.pone.0006001.t001
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donors are favorable (NH and OH groups in the ligand). Orange
polyhedra surround the area where H-bond acceptor is unfavor-
able and white polyhedra the area where H-bond donor is
unfavorable. In the Class I contour map (Figure 4C) the
importance of the hydrogen bond acceptor interaction can be
seen at both ends of the molecules, in the positions of the oxygen
within the esteric group and in the position of the epoxy or etheric
oxygen on the other side. This is also seen when the ED50 values of
compounds 15 and 22 are compared. The only difference
between these two compounds is that an esteric oxygen (a
hydrogen bond acceptor) is replaced by an amidic nitrogen (a
hydrogen bond donor), which leads to 100-fold decrease in the
biological activity of 22. This is also apparent from both of the
CoMFA and CoMSIA electrostatic contour maps in which a
negative charge enhances activity (red color). When these
electronegative atoms in Class I structures are replaced by carbon
(e.g. compounds 21, 25, 26, 29, 31, 32) or distance between these
electronegative end points was shorter than 11.5 A ˚ or longer than
13.5 A ˚ (compounds 28, 40, 41, 48, 49), biological activity
dropped down dramatically. In addition, the presence of an
electronegative oxygen or a double bond in the middle of the
structure (e.g. 9, 15, 17) which results in a site with an increased
concentration of negative charge, and less electron charge at the
ends, also seems to be important for biological activity. These
areas are represented by blue polyhedra on the CoMFA and
CoMSIA contour maps. The contour map of Class II lacks
polyhedra for a favorable H-bond donor or acceptor field on
phenoxyphenol side of structures. The CoMFA and CoMSIA
calculations indicated that the electrostatic requirements are more
important than the steric ones because of the electrostatic fraction
had higher values than the steric fraction for both Class I and
Class II (Tables 1 and 2). The CoMFA electrostatic fraction is
0.574 versus a steric fraction of 0.426. This is even more
remarkable in the CoMSIA calculation where the electrostatic
fraction is 0.740 while the steric fraction is 0.260. Thus, the crucial
element that contributes to high affinity binding is the presence of
negative charge-rich atoms or groups at the ends of the molecules
represented by electronegative atoms of oxygen, nitrogen, or
unsaturated cycle. As this is also supported from CoMSIA field
indices and hydrogen bond acceptor fractions (Table 2), these
electronegative atoms are most probably involved in hydrogen
bonding with the putative receptor. Thus, the analysis of CoMFA
and CoMSIA models for Class I+II revealed the points and
regions that are highly correlated to the activity of tested
compounds. These data from 3D QSAR analyses suggested two
pharmacophore models that depict the key structural requirements
for the biological activity of JH agonists (Figure 5A and 5B).
Table 2. Summary of results from CoMSIA analyses for a training set of 76 JH agonists.
Cross-validated Non- cross-validated Fraction
Class n comp q
2 SPRESS r
2 SEE F test S E DA
I+II
S 76 2 0.371 1.065 0.744 0.805 31.07
E 76 3 0.507 0.882 0.884 0.651 61.77
SE 76 6 0.534 0.877 0.901 0.408 96.76 0.26 0.74
A 76 3 0.391 1.072 0.667 0.725 45.42
SEDA 76 3 0.485 0.901 0.736 0.643 63.86 0.08 0.36 0.56
I
S 45 3 0.385 1.009 0.786 0.721 29.91
E 45 6 0.551 0.934 0.926 0.396 70.80
SE 45 6 0.637 0.875 0.960 0.290 136.18 0.29 0.71
A 45 2 0.329 1.192 0.625 0.915 29.94
SEDA 45 3 0.493 1.050 0.860 0.623 49.58 0.05 0.23 0.72
II
S 31 6 0.755 0.678 0.956 0.286 87.37
E 31 2 0.675 0.722 0.841 0.505 74.23
SE 31 2 0.695 0.700 0.927 0.396 78.38 0.20 0.80
A 31 3 0.537 0.878 0.836 0.522 45.91
H 31 6 0.660 0.798 0.978 0.205 174.16
DA 31 3 0.481 0.930 0.843 0.511 48.28
SEDAH 31 3 0.579 0.837 0.887 0.435 70.31 0.07 0.25 0.51
Legend:
n=number of compounds.
Comp=number of PLS components in analysis.
q
2=Squared correlation coefficient of a cross-validated analysis.
SPRESS=Standard deviation of error of prediction.
r
2=Standard correlation coefficient of a non-cross-validated analysis.
SEE=Standard deviation of a non-cross-validated analysis.
Fraction=Field contribution from CoMSIA like S=steric, E=electrostatic, A=hydrogen bond acceptor type, D=hydrogen bond donor type, H=hydrophobic.
doi:10.1371/journal.pone.0006001.t002
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We then used the pharmacophore model with the PrGen
program to produce an atomistic pseudoreceptor model. This
model contains the essential features of an active site by assuming
complementarity between the shape and properties of the receptor
site and the bioactive conformations of the set of JH compounds,
and thus mimics the real receptor binding surface. The alignments
of natural JH-III, the five most active ligands of Class I, and the six
most active ligands of Class II were used to generate correspond-
ing pseudoreceptors. We selected the appropriate amino acid
residues for pseudoreceptor construction by considering two
important factors. First, we used data derived from the CoMFA
and CoMSIA structure-activity relationships. Second, we used
information about which amino acids are most frequently involved
in forming interactions between members of the nuclear receptor
superfamily and small lipophilic ligands. Based on these criteria,
polar amino acids (e.g. Arg, Asp) were placed complementarily to
the vectors of atoms with local electron deficit, and residues acting
as H-bond donors (e.g. Tyr, Asn) were placed complementarily to
the vectors of esteratic or etheric oxygens. Hydrophobic amino
Figure 3. CoMFA steric and electrostatic fields contour plot for Class I and Class II JH agonists. Green polyhedra represent sterically
favored regions where more bulky substituents increase biological activity, while yellow polyhedra surrounded regions indicate sites where less bulky
substituents are appreciated for increasing biological activity. Blue polyhedra represent electrostatic regions where positively charged groups will be
favorable and will enhance biological activity, whereas the red contours represent regions where negative charge is favorable. The importance of the
electronegative oxygens or nitrogens on the ends of the aligned structures is indicated by red polyhedra near the positions of these atoms. The
presence of smaller red polyhedra in the middle of the JH agonist structure indicates an additional site where an electronegative atom or group can
enhance biological activity. The contour map of Class II (B) differs from that of Class I (A) mainly in the steric fields. The large green polyhedra of Class
II (B) near the part of the phenoxyphenyl group (left side) indicates that the presence of steric bulk substituents in this part of the molecule enhances
biological activity.
doi:10.1371/journal.pone.0006001.g003
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rest of the molecular alignment. For acceptor type of hydrogen
bond interactions, we used bonding with Ser, Thr, Tyr, His, Arg
or Gln, and we used Ser, Thr, Tyr, His, Arg, Gln, Lys or Asp to
mediate electrostatic interactions. After the whole complex of a
pharmacophore surrounded by an active site was generated, the
energy equilibration protocol was applied to produce an
energetically relaxed model until the best possible correlation
between calculated and experimental free energy of ligand binding
could be achieved. A variety of physical phenomena are thought to
contribute to the binding affinity (KB) of an interaction, including
those that are considered to make a largely enthalpic contribution,
for example, van derWaals interactions, hydrogen bonding and
electrostatic complementarity, and those considered to be
dominated by entropy, for example, changes in configurational
disorder and in the solvation of hydrophobic/lipophilic groups
upon formation of the complex [34,35]. The binding affinity, or
equilibrium binding constant (KB), describes the ratio of concen-
tration of a complex (PL) at equilibrium for a reversible reaction
between free protein (P) and ligand (L) KB=[PL]/[P] [L]. At
equilibrium under conditions of constant pressure, the binding
constant KB is related to the standard Gibbs free-energy change
(DG
o) of the reaction through DG
o=2RTlnKB where R is the gas
constant (8.314472 J mol
21 K
21) and T is the temperature (in
Kelvin) [36]. The conversion of the dissociation constant Kd to
free- energy of binding is apparent from equation DG
o=RTlnKd
[37]. The more negative the value of DG
o, the more favorable the
reaction. The change in free energy itself is composed of enthalpic
(DH
o, effectively, the heat given out or taken up upon making and
breaking bonds) and entropic (DS
o, which represents the energetic
consequences of changes to the degree of order within the system)
changes, where DG
o=DH
o2TDS
o [34,38]. To find the optimal
energy equilibrium, this procedure was repeated iteratively with
each amino acid combination selected for their appropriate
positions at the tips of vectors.
A combination of Trp, Thr, Leu, Thr, Leu, Ile, Val and Tyr
amino acid residues yielded the best correlation coefficient
(r
2=0.91) and had a predictive cross-validated coefficient of
q
2=0.53 between the experimental free energies of binding and
predicted free energies of binding for an atomistic pseudoreceptor
Figure 4. Contour maps of Class I and Class II JH agonists CoMSIA analyses. Green polyhedra represent sterically favored regions in which
more bulky substituents will increase biological activity, while yellow polyhedra represent sterically disfavored regions where less bulky substituents
are appreciated for increasing the activity of both Class I (A) and Class II (B) JH agonists, respectively. In the electrostatic contour plot, the red
polyhedra represent favorable regions where negatively charged groups will enhance activity and the blue polyhedra represent disfavored regions
where positively charged groups will enhance activity. Contour maps for the hydrogen bond acceptor and donor fields are illustrated in C (for Class I
agonists) and D (for Class II agonists). Magenta areas indicate regions where hydrogen bond acceptors are favorable for increasing biological activity
(oxygens and nitrogens in the ligand), cyan areas indicate fields where hydrogen bond donors are favorable (NH and OH groups in ligand). Orange
polyhedra surround area where H-bond acceptors are unfavorable and white polyhedra areas where H-bond donors are unfavorable.
doi:10.1371/journal.pone.0006001.g004
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bond donors Tyr and Thr are positioned in the vicinity of the
esteratic or amidic group of the aligned molecules, Tyr is
positioned near the epoxy group on the opposite site of the
molecular alignment. Trp is positioned optimally near the electron
deficient middle part of the Class I alignment. When the same
procedure was applied to data from the Class II pharmacophore
model, a combination of Tyr, Met, Val, Val, Thr, Leu, Phe and Ile
amino acid residues yielded the best statistical correlation
coefficients r
2=0.92 and cross-validated predictive coefficient
q
2=0.43. As in the pseudoreceptor model based on the Class I
structures, in the model based on Class II structures (Figure 6B)
Thr is placed as a hydrogen-bond donor in the vicinity of the
esteratic or amidic group of the agonist alignment, and Tyr is
placed near the middle electron deficient region. The hydrophobic
residues (Ile, Phe, Leu) are positioned against the phenoxyphenyl
group. The theoretical relative Gibbs free energies calculated for
the binding of both series of agonists vs experimental relative Gibbs
energies are shown in Tables 3 and 4.
Discussion
This study sought to establish an initial juvenoid 3D QSAR by
CoMFA and CoMSIA models of extensive molecule set. Early
trials to look at action of JH agonists via structure-activity
relationships confronted several issues [19,39–41]: (i) The largest
obstacle was in testing, collecting and comparing data simulta-
neously among several species. Especially at the early stages of an
analysis of structure-activity relationships, this approach hampered
the ability of obtaining interpretable data specific for a given insect
species. Since the molecular mode of JH action relies on an
interaction between a small ligand and its protein target, there are
likely species-specific differences in amino acid sequence and
protein structure that makes it extremely difficult to develop a
pharmacophore model useful for predicting the molecular
properties of a JH receptor. (ii) A second and often neglected
problem was involved in selecting the characteristic used to
measure ID50,I C 50 or ED50. For simplicity and efficient data
collection, researchers were frequently satisfied with counting the
inhibition of metamorphosis or the prevention of eclosion. These
easily could reflect a compound’s insecticidal toxicity rather than
its morphogenetic action, generating misleading data. (iii) A third
problem is associated with method of juvenoid application. This
can make a crucial difference in testing JH biological activity. For
example, very different dose-response curves and ID50 or IC50
values will be obtained when animals are given a tested
compounds via a single direct topical application than via its
continuous presence in food or the living environment (e.g. in the
water for aquatic insects [42]). Under conditions where a
compound is continuously present, there is an increased chance
that toxic effects will have prevalence over realistic biological
activity. (iv) Until now, structure-activity studies focused on testing
JH analogs in agricultural pests or disease vectors that, in contrast
to Drosophila, could not provide suitable genetic or molecular tools
to dissect the molecular mode of JH action. There is good chance
that combination of present approach with the power of Drosophila
genetics can be explored in near future. (v) Finally, versatile
bioinformatics-aided computer programs to evaluate data were
unavailable when there was highly active research on developing
JH analogs. To avoid these pitfalls, we chose to use just one insect
species, and chose Drosophila since it is a well characterized genetic
model. To be certain we were evaluating real hormonal activity of
compounds, we used a strictly defined, specific morphogenetic
effect [23,25,27,43] as a criterion for our ED50 calculations.
Finally, to avoid any misinterpretation, we generated, collected,
processed and evaluated all data in using a well-established 3D
QSAR computational approach exclusively within our research
group.
In many recent CoMFA and CoMSIA studies, researchers have
analyzed data sets from in vitro assays where a recombinant
receptor is used and transiently expressed in host cells and where a
series of compounds is tested for reporter activity. While this
approach makes predictions much easier and straightforward to
test, and is widely used in drug development, lipophilic
compounds pose a unique challenge. Here, we employed a reverse
approach where quantitative structure-activity data and results
from CoMFA/CoMSIA analyses shed light on the properties of a
putative JH receptor.
For a long time, it has been thought that the biological activity
of JH analogs in in vivo tests is strongly affected by their solubility,
penetrance through cuticle, transport via hemolymph and delivery
to target tissues (for reviews see [18–20,22,44]). In fact, many of
these conclusions were based on the lipophilic properties of JH
compounds and analogs. Notwithstanding this potential compli-
Figure 5. Pharmacophore models of Class I and Class II JH
agonists based on CoMFA and CoMSIA result. Models show key
structural elements responsible for the hormonal activity of JH agonists.
Both classes of JH compounds share regions that favor negative charge
and a field that requires hydrogen bond acceptor. In both cases these
elements are located at the sides of JH agonists. However, Class I
compounds (A) have also additional hydrogen bond acceptor element
located on the esteratic side, and a region which favors positive charges
centrally. A specific feature of Class II compounds (B) is a hydrophobic
region that is favored around the outside edge of a phenoxyphenol
moiety. Due to the high flexibility of Class I compounds the distance
between hydrogen bond acceptor atoms (e.g. esteratic and epoxy
oxygens at two sides) must be between 11.5 and 13.5 A ˚ to possess
agonist biological activity in Drosophila. Highly rigid Class II compounds
that show JH biological activity in Drosophila automatically fit to this
requirement.
doi:10.1371/journal.pone.0006001.g005
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PLoS ONE | www.plosone.org 9 June 2009 | Volume 4 | Issue 6 | e6001Figure 6. Three-dimensional structure of the pseudoreceptor models for Class I (A) and Class II (B) JH agonists. Selected compounds
are aligned in the middle with the surrogate of eight amino acids surrounding them. Both models are composed of eight amino acid residues
reflecting all interactions that are predicted to be required from pharmacophore analysis. For the sake of clarity, bonding interactions and vectors
have not been displayed.
doi:10.1371/journal.pone.0006001.g006
Table 3. DG Experimental versus DG PrGen predicted
activities for JH agonists of Class I.
Comp. No DGexp DGpred
1 2.02 1.44
2 21.09 21.42
8 22.17 22.72
9 25.25 24.70
15 3.40 3.86
19 2.54 1.73
doi:10.1371/journal.pone.0006001.t003
Table 4. DG Experimental versus DG PrGen predicted
activities for JH agonists of Class II.
Comp. No DGexp DGpred
53 22.05 22.08
54 21.90 22.16
56 21.50 21.80
82 22.41 21.98
84 22.26 21.08
86 23.98 23.94
doi:10.1371/journal.pone.0006001.t004
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demonstrate the hydrophobic and donor-acceptor interactions of
Class I JH agonists have very poor q
2 and r
2 values. It is already
known that these interactions, under certain circumstances, may
reflect non-specific interactions of biological molecules such as
solubility, penetrance, and transport etc. [45–50]. In contrast, the
highly significant q
2 and r
2 values for the steric and electrostatic
fields document that the QSAR data obtained reflect the real
binding of a ligand to its protein target, possibly a receptor, rather
than non-specific interactions [51]. Two important considerations
shed light on this result. First, JH compounds that show biological
activity are active at relatively low concentrations, concentrations
that are below the threshold that would produce additive or non-
specific effects. This is consistent with the negligible role that
hydrophobic interactions are observed to play in biological
activities. Secondly, the composition of the Drosophila exoskeleton
(its cuticular layers) [52,53] appears to be relatively favorable for
JH penetrance and offers little if any resistance to hormonal
effects. This notion is supported by the observation that the
application of JH compounds topically or in drinking water
renders a very different biological activity response in different
insects (e.g. to the linden bug, Pyrrhocoris apterus [18,20]). Therefore,
3D QSAR analysis of in vivo biological activities of juvenoids in
insects from other systematic groups may not be as effective in
developing CoMFA or CoMSIA models.
One of the most fascinating questions in research on JH agonists
has been to understand what these structurally divergent
compounds have in common that enables them to retain identical
biological activity? Our pharmacophore model based on SAR of
the most active Class I agonists has 5 elements. These 5 elements
are: (i) acceptor type of hydrogen bond related to esteratic or
equivalent oxygen (as shown from studies with 17, 23 and 24); (ii)
a second acceptor hydrogen bond originating from the epoxy
oxygen on the opposite side of the molecule (as apparent in 35);
(iii) an electrostatic interaction from a carbonyl (keto) oxygen on
the same side of the molecule (see 1–12, 15, 17, 20, 22, 25, 26)
which potentially may become hydrogen bonding element; (iv) a
strict distance (11.5–13.5 A ˚) between these hydrogen acceptor
oxygens or nitrogens; (v) positively charged groups are favored in
the middle of the molecule. JH-III as a natural ligand has only 4 of
these elements which explains why several JH agonists, in addition
to commonly known resistance to metabolism [12,18,20], can be
more potent than natural JH. Our pharmacophore model of Class
II agonists has 3 elements: (i) as for Class I agonists, the first
element is a hydrogen bond acceptor on the right side of the
ligand; (ii) a negatively charged group on the opposite side of the
pharmacophore; and (iii) a bulky hydrophobic region on the same
side where the phenoxyphenol moiety is usually found.
Pseudoreceptor modeling [54–56] is one of several receptor
mapping approaches, where a paucity of information concerning
receptor structures has spawned techniques that project the
properties of the bioactive ligands into three dimensions around
their appropriately superimposed molecular framework. The
molecular nature of natural JH and its agonists (similar to
retinoids, free fatty acids and steroids) and the type of interactions
predicted from pharmacophore models strongly argue that the
ligand binding pocket of the receptor for JH holds properties that
are similar to members of nuclear receptor superfamily. Consistent
with this, we constructed a pseudoreceptor ligand-binding site by
using information about the amino acids most frequently involved
in forming interactions with small lipophilic ligands in nuclear
receptors [57–60]. To achieve the optimal positions of the selected
residues, a receptor equilibration was subsequently performed
allowing for translation, rotation, and torsional variations of
receptor’s amino acid residues. The resulting map provides steric,
electrostatic, and lipophilic profiles used to identify the type and
approximate position of receptor residues, or their functional
groups, interacting with the ligand. This map can be used for
subsequent molecular modeling and allows for semiquantitative
predictions of binding affinities for ligands. The structure of the
resultant complex contains 8 amino acid residues that span the
alignment of Class I as well as Class II JH agonists. Both models of
a three-dimensional receptor surrogate have been validated,
leading to high correlation and predictive power as well as a
perfect agreement with the pharmacophore models. Therefore,
the data that are presented here have allowed for the first time the
rationalization of JH-agonist SAR not only at a qualitative level
but also provided quantitative relationships between the structure
of JH compounds and their biological activity as summarized and
reflected in likelihood models of the docking pocket of a putative
JH receptor. We believe that this approach, in combination with
3D-object recognition based on scanning, pairwise comparison or
similar protocols [61,62] to identify the spatial coordinates of
individual atoms can be used in the near future to find potential
siblings in structural databases.
Materials and Methods
All experiments have been performed on the wild-type strain
Oregon R of Drosophila melanogaster. JH and JH agonists (for complete
list see Supporting Table S1), dissolved in acetone were applied
topically in 0.5 ml onto the abdominal surface of late wandering
3rd instar larvae. Details on testing and evaluation, including the
processing of animals for light and electron microscopy are
provided in the Supporting Experimental Procedures S1 and
References S1.
CoMFA and CoMSIA computations were performed with the
molecular modeling software package Sybyl ver 6.8 (Tripos Co.,
St. Louis, MO, USA) on a Silicon Graphics Origin 2000 (R10000)
and O2 (R10000) servers. The AM1 semiempirical method was
applied for geometrical optimization and calculation of the partial
atomic charges.
Molecular alignment
Structural alignment is the most critical step in CoMFA study
and the resulting model is often sensitive to a particular alignment.
While it is recognized that the global energy-minimum confor-
mation may not necessarily be adopted in the drug-receptor
complex, the use of a reasonably low energy conformation in the
alignment is a useful starting point for statistical comparisons of
flexible structures within both the CoMFA and the CoMSIA
models. In this study, we took lowest energy conformation of the
most rigid and highly active molecule (No. 82) as the template
structure for the alignment. Molecules were superimposed by
minimizing the root mean square (RMS) distance between atom
pairs that belongs to the fitting molecule and to template molecule,
respectively, and the alignment for all 86 compounds within the
test set is shown in Figure 2A. Superimposition of ligands was
based on manually selected overlapping oxygens or nitrogen at the
ends and quaternary or sp
2 hybridized carbon in the middle of the
structures (Figure 2B).
CoMFA analysis
The CoMFA analysis of this set of molecules was carried out on
the steric and electrostatic fields using the standard options of
Sybyl 6.8 package. A three dimensional cubic lattice with a 2 A ˚
grid spacing was generated automatically around aligned mole-
cules with the grid extending molecular dimensions up to 4 A ˚ in all
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separately for each molecule using sp
3 hybridized carbon atom
with charge of +1. Energy cut off value of 30 kcal/mol was
applied, which means the calculated energies greater than
30 kcal/mol are truncated to this value and thus avoiding infinity
of energy values inside molecule. Partial least squares (PLS)
method was used to analyze the relationship between the
calculated steric and electrostatic energies and 2log ED values.
The crossvalidation PLS calculation was performed by a Leave-
One-Out (LOO) procedure. To speed up the analysis and reduce
noise, column filtering was set at 1.0 kcal/mol so that only those
steric and electrostatic energies with values greater than 1.0 kcal/
mol are considered in the PLS analysis. To maintain the optimum
number of PLS components and minimize the tendency to overfit
the data, the number of components corresponding to the lowest
Predictive Error of Estimate (PRESS) value was used for deriving
the final PLS regression models. Cross-validation determines the
optimum number of components, corresponding to the smallest
error of prediction and the highest cross-validated q
2. The analyses
were carried out with a maximum of ten components, and
subsequently, using the optimal number of components at which
the difference in the q
2 value to the next one was less than 5% and
error of prediction was the lowest one. The models were estimated
on the crossvalidated LOO r
2 (expressed as q
2), standard error of
prediction, SEP, the non-crossvalidated conventional correlation
coefficient r
2, and the standard error of estimate SEE.
The overall predictive ability of the analysis was evaluated by
the term q
2 which was calculated according to following equation:
q2~1{
P
Y Ypred{Yact
   2
P
Y Yact{Ymean ðÞ
2
Whenever crossvalidation is used in conjunction with PLS, some
above indices change and others are omitted as meaningless. The
key difference is in the definition of standard error s value. In
analysis without crossvalidation the standard error is uncertainty
remaining after least squares fit has performed. In crossvalidation,
standard error becomes the expected uncertainty in prediction for
the individual compound based on the data available from other
compounds. In this context s becomes the root mean Predictive
Error of Estimate (PRESS). It is harder to predict values which are
not used in deriving a model than it is to fit the same values which
including the minimum model, and the crossvalidated correlation
coefficient q
2 is always much lower than the conventional
correlation coefficient r
2. Uncertainty of prediction is defined as:
SPRESS~
PRESS
n{k{1 ðÞ
However, PRESS and q
2 are generally proving to be better
indicators than standard error and r
2 of how reliable predictions
actually are. A model with a q
2 value greater than 0.3 is usually
considered to be significant. The CoMFA steric and electrostatic
fields of the analysis are present as contour maps (Figure 3). The
color polyhedra surround those lattice points where the QSAR
strongly associates changes in compound field values with changes
in biological potency. In the maps, color polyhedra surround the
lattice points in which QSAR identifies fields where compounds
have significant changes in biological activity. Green polyhedra
represent sterically favored regions where more bulky substituents
increase biological activity, while yellow polyhedra surround
regions where less bulky substituents are able to increasing
biological activity. Blue polyhedra represent electrostatic regions
where positively charged groups are favorable and enhance
biological activity, whereas the red contours represent regions
where negatively charged groups are favorable.
CoMSIA analysis
Analogous to CoMFA, a data table is constructed from
similarity indices calculated at the intersections of a regularly
spaced lattice 2 A ˚ grid in CoMSIA. Unlike CoMFA, CoMSIA
uses the Gaussian function for the distance dependence between
the probe atom and the molecule atoms to avoid some of the
inherent deficiencies arising from the functional form of the
Lennard-Jones and Coulomb potentials. We take into evaluation 5
physicochemical properties: steric (S), electrostatic (E), hydropho-
bic (H), hydrogen-bond donor (D) and acceptor (A) properties.
Using all five CoMSIA descriptors for the explanatory variables, a
LOO run and a novalidation-PLS analysis were performed. These
five different fields help to increase the model’s significance and
predictive power as well as to partition the various properties into
the spatial locations where they play a decisive role in determining
biological activity. Similarity indices AF,K between the compounds
and a probe atom are calculated according equation:
A
q
F,k j ðÞ ~
X
i
wprobe,kwike
{arZ
iq
where q is the grid point for molecule j, with the summation index
over all atoms of the molecule j; wik the actual value of
physicochemical property k of atom i; wprobe,k indicates probe
atom with charge +1, radius 1 A ˚, hydrophobicity +1; H-bond
donor and acceptor property +1; a is the attenuation factor,
default is 0.3; riq is the mutual distance between probe atom at grid
point q and atom i of the test molecule [33]. Using all five
CoMSIA descriptors for the explanatory variables, a LOO run
and a novalidation-PLS analysis were performed. The models
were estimated on the crossvalidated LOO q
2, standard error of
prediction (SPRESS), the non-crossvalidated conventional corre-
lation coefficient r
2, and the standard error of estimate (SEE). The
color polyhedra surround those lattice points where the QSAR
strongly associates changes in compound field values with changes
in biological potency.
Pharmacophore and pseudoreceptor model generation
Using the results of CoMFA and CoMSIA, we have proposed a
putative pharmacophore model that explains the key structural
requirements for the activity of JH and its agonists. To refine this
pharmacophore models the program PrGen (3R Biographics
Laboratory Foundation, Basel, Switzerland) was used to generate
the pseudoreceptor. Based solely on the structures of ligand
molecules this method aims to predict the relative free energies of
binding. The model is validated by its ability to reproduce the
experimental data of the set of ligands. The 3D coordinates of JH-
III and five most active JH agonists from Class I and six most
active JH agonists from Class II superimposed in the conforma-
tions from the CoMFA study were used in the alignment for
PrGen pseudoreceptor modeling. From the overlapped ligands,
the program generates vectors for each functional group indicating
steric, electrostatic, and lipophilic interactions. Pseudoreceptor is
then created from individually chosen residues that are positioned
at the tips of the vectors. Residues were chosen specifically to fit
the type of interaction of each vector as characterized by
overlapped molecules and CoMFA based pharmacophore. The
experimental free energies of ligand binding were calculated
according to methodology reported by Vedani et al. [55], Bassoli et
al. [63] and Zbinden et al. [64]. Experimental free energies of
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DGexp~RT ln Kd
where Kd is experimental dissociation constant. The dissociation
constants of JH agonists are unknown, for this reason dissociation
constant Kd was approximated by lnED50.
In PrGen, free energies of binding, DG0, are estimated from
equation:
Ebinding~Eligand-receptor{T DS{DGligand solvationzDEinternal ligand
Algorithms to calculate these quantities are included in PrGen.
Predicted free energies of ligand binding, DGpred, are obtained by
means of a linear regression between DGexp and Ebinding:
DGpred~aE bindingzb
The resulting complex of superimposed ligand molecules and
amino acids residues of the pseudoreceptor was optimized by a
conformational search protocol combined with energy minimiza-
tion. This step is repeated until the functional groups interact with
a pseudoreceptor residue. An interactive algorithm, equilibration
protocol, is used to obtain the best correlation between
experimental and predicted free energies of binding.
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Supporting Information
Figure S1 Comparative plot of experimental versus CoMFA
predicted biological activities (2log ED50) of common training set
(Class I+II) of 76 JH agonists. Despite being structurally diverse,
mostactivecompoundsinDrosophila sharesome commonfeatures,
i.e. an electronegative atom (oxygen or nitrogen) at one end of the
molecule and electronegative atom (epoxy oxygen) or electron rich
moiety (oxyphenyl group) on the molecule’s opposite end (see
compounds 1–3, 14–17, 19, 81–86). Nonetheless, the terpenoid and
rigid phenoxy structures have very different chemical reactivity,
atom charges and abilities in forming hydrogen bonds or
electrostatic interactions. Indeed, this was one major reason to
divide the complete training set into two classes. The oxygen in
phenoxyphenol group of Class II compounds is sterically hindered
by benzene rings that makes the phenoxyphenol oxygen poorly
reactive for intermolecular hydrogen bonding, while the oxygen
within an epoxy moiety of Class I compounds can easily provide
electron pairs for H-bonding or for other electrostatic interactions.
The difference between Class I and II analogs is reflected also in
their negative charge distribution. In the Class I structures it is
concentrated near electronegative, ether or epoxy oxygen whereas
in Class II structures it is localized to the phenyl rings. Indeed, a
similar protocol for subdividing compounds into two chemotypes
for QSAR analyses was published recently for COX-2 inhibitors
[41] and steroid hormones to reflect the unusual conformational
adaptation of nuclear receptor ligand binding domains to agonist
variety [42,43]. Furthermore, the presence of an electron deficient
moiety in the middle of the JH agonist molecule is essential for the
very high biological activity seen in some synthetic JH agonists but
not observed in natural JH (blue and cyan polyhedra regions in
CoMFA and CoMSIA contour maps, respectively; see Figures 3
and 4A, B). On the other hand, the steric CoMFA and CoMSIA
contour maps indicate that presence of more bulky substituent in
Class I compounds (green polyhedra) will enhance their biological
activity. More bulky substituent (yellow polyhedra) near the
phenoxyphenyl or epoxy groups in Class II compounds would
decrease their biological activity (as again shown in Figures 3B and
4B). Thus, it is significant that each of these two independent
training sets have shown a nearly ideal alignment and markedly
better statistical parameters than the original common set.
Found at: doi:10.1371/journal.pone.0006001.s001 (2.99 MB TIF)
Figure S2 Graphical representation of observed versus CoMFA
predicted biological activities (2log ED50) for training set of Class I
JH agonists.
Found at: doi:10.1371/journal.pone.0006001.s002 (2.99 MB TIF)
Figure S3 Correlation between experimental and CoMFA
predicted biological activities (2log ED50) for training set of Class
II JH agonists.
Found at: doi:10.1371/journal.pone.0006001.s003 (2.99 MB TIF)
Figure S4 Graphical representation of observed versus CoMSIA
predicted biological activities (2log ED50) for training set of Class
I JH agonists. The difference between Class I and Class II agonists
in their hydrogen bonding availability is markedly visible in the
CoMSIA hydrogen bond contour maps (for comparison see
Figures 4C and 4D). There is a significant difference between
Class I and Class II molecules in the large green area in the steric
contour maps of both CoMSIA and the CoMFA (see also
Supporting Figure 5). For Class I compounds the green area in this
part of the structures is much smaller, and so it could signify a
tighter contact with the receptor binding site.
Found at: doi:10.1371/journal.pone.0006001.s004 (2.99 MB TIF)
Figure S5 Experimental versus CoMSIA predicted biological
activities (2log ED50) for training set of Class II JH agonists. The
significant difference between Class I and Class II molecules in the
large green area in the steric contour maps of both CoMFA and
the CoMSIA indicates that more bulky substituents in these
regions will enhance the biological activity in Class II compounds.
This might lead us to presume that there is a bigger or more
flexible binding-site cavity surrounding this region in the agonists.
The CoMSIA and also CoMFA generated steric and electrostatic
contour maps have the potential to indicate the shape and surface
requirements of the JH binding protein cavity, the putative JH-
receptor. From this, we can infer that the receptor cavity must
have charged residues lengthwise along its borders and negatively
charged or neutral residues in its middle.
Found at: doi:10.1371/journal.pone.0006001.s005 (2.99 MB TIF)
Experimental Procedure S1
Found at: doi:10.1371/journal.pone.0006001.s006 (0.05 MB
DOC)
Pharmacology of JH Agonists
PLoS ONE | www.plosone.org 13 June 2009 | Volume 4 | Issue 6 | e6001Table S1
Found at: doi:10.1371/journal.pone.0006001.s007 (0.24 MB
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Table S2
Found at: doi:10.1371/journal.pone.0006001.s008 (0.03 MB
DOC)
Table S3
Found at: doi:10.1371/journal.pone.0006001.s009 (0.02 MB
DOC)
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Found at: doi:10.1371/journal.pone.0006001.s010 (0.02 MB
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Found at: doi:10.1371/journal.pone.0006001.s011 (0.02 MB
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